Prochlorperazine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Nausea and vomiting As prochlorperazine mesylate/maleate: Prophylaxis: 5-10 mg bid or tid. Treatment: Initially, 20 mg, followed by 10 mg after 2 hours, if necessary. < Vertigo As prochlorperazine mesylate/maleate: In patient with Meniere's syndrome, labyrinthitis: 5 mg tid, increased up to 30 mg/day. Reduced dose gradually to 5-10 mg after several weeks. Adjunct in severe anxiety disorders As prochlorperazine mesylate/maleate: Initial: 15-20 mg/day in divided doses, increased to Max 40 mg/day, if necessary. Schizophrenia; Mania As prochlorperazine mesylate/maleate: Initial: 12.5 mg bid for 7 days, increased at 4-7 days interval until satisfactory response is achieved. Usual dose: 75-100 mg/day. IM Nausea and vomiting As prochlorperazine mesilate: 12.5 mg via deep inj, may give further doses via oral admininistration, if necessary. As prochlorperazine edisylate: Initial: 5-10 mg, if necessary, may repeat dose 3-4 hourly. Max: 40 mg daily. Schizophrenia; Mania As prochlorperazine mesilate: 12.5-25 mg bid or tid via deep inj. As prochlorperazine edisylate: Initially, 10-20 mg via deep inj, may repeat dose 2-4 hourly, if necessary. IV Nausea and vomiting As prochlorperazine edisylate: 2.5-10 mg via slow inj or infused at a rate not exceeding 5 mg/min. Max: 10 mg/dose; 40 mg/day. Rectal Severe nausea and vomiting 25 mg bid.
Administration
May be taken with or without food.
Contraindications
Reye's syndrome, comatose patients. Children <2 years or weighing <9 kg.
Special Precautions
Patient with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, visual problems, stroke, cerebrovascular disease, severe CV disease, dementia, Parkinson's disease, hypothyroidism, cardiac failure, phaeochromocytoma, myasthenia gravis, prostate hyperthrophy. hypovolaemia, epilepsy or history risk of seizures. Children and elderly. Renal and hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness, if affected, do not drive or operate machinery. Avoid exposure to extreme heat. Monitoring Parameters Monitor for electrolytes, CBC, LFT, fasting plasma glucose level, lipid panel, visual changes. Discontinue treatment if neutrophil count is <1,000/mm3. Monitor for changes in mental status, vital signs, weight, BMI, waist circumference, tardive dyskinesia, changes in menstruation, libido, development of galatorrhoea, erectile and ejaculatory function, fever, muscle rigidity, autonomic instability.
Adverse Reactions
Significant: Cholinergic effects (e.g. constipation, xerostomia, blurred vision, urinary retention), aspiration of vomit, extrapyramidal symptoms, somnolence, orthostatic hypotension, motor instability, hyperprolactinemia, pigmentary retinopathy, lenticular or corneal deposits, impaired body temperature regulation. Endocrine disorders: Amenorrhoea. Gastrointestinal disorders: Nausea, obstipation, intestinal obstruction, vomiting. Hepatobiliary disorders: Jaundice. Immune system disorders: Angioedema, urticaria. Metabolism and nutrition disorders: Hyponatraemia, hyperglycaemia. Nervous system disorders:Acute dystonia, dyskinesia, parkinsonism, tardive dyskinesia, agitation, convulsion. Psychiatric disorder: Akathisia, insomnia. Renal and urinary disorders: Urinary retention. Reproductive system and breast disorder: Impotence, ejaculatory disorder. Respiratory, thoracic and mediastinal disorders: Respiratory depression. Skin and subcutaneous tissue disorders: Contact dermatitis, rash.
Potentially Fatal: Arrhythmias, torsade de pointes, blood dyscrasias (e.g. leucopenia, neutropenia, agranulocytosis), hypotension, neuroleptic malignant syndrome (e.g. hyperpyrexia, muscle rigidity, altered mental status).
Drug Interactions
Enhanced CNS depression with barbiturates and sedatives. Reduced antipsychotic effect with anticholinergics. May reduce the effect of hypoglycaemic agents. Increased risk of arrhythmias with antidepressants. Increased risk of agranulocytosis with carbamazepine. Increased neurotoxicity with lithium. Diminished therapeutic effect of oral anticoagulant. Decreased absorption with antacids.
ATC Classification
N05AB04 - prochlorperazine ; Belongs to the class of phenothiazine antipsychotics with piperazine structure.
Disclaimer: This information is independently developed by CIMS based on prochlorperazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in